Teva Pharmaceutical Stock Hits 52-Week High On Credit Ratings Lift - Teva Pharmaceutical Indus (NYSE:TEVA)

Teva Pharmaceutical Stock Hits 52-Week High On Credit Ratings Lift - Teva Pharmaceutical Indus (NYSE:TEVA)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) said on Wednesday that S&P Global Ratings upgraded its long-term issuer credit rating to BB+ from BB with a stable outlook, while Moody's affirmed its Ba1 rating and revised the outlook to positive. The actions reflect Teva's steady deleveraging and improving operating performance. Delevaraging S&P noted adjusted leverage fell to 4.4x as of Sept. 30, 2025, and expects it to decline below 4.25x in t…

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline.Moody's affirmed Teva's B1a rating and revised Teva's outlook to positive from stableS&P upgraded Teva to BB+ from BB, with a stable outlook

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody’s Ratings Agency Revises Outlook to Positive

The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline.Moody's affirmed Teva's B1a rating and revised Teva's outlook to positive from stableS&P upgraded Teva to BB+ from BB, with a stable outlook